Randomized Controlled Trial
doi: 10.1177/0009922806292792.
Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD)
Affiliations
- PMID: 16968960
- DOI: 10.1177/0009922806292792
Item in Clipboard
Randomized Controlled Trial
Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD)
Clin Pediatr (Phila).
2006 Oct.
Abstract
An age-appropriate questionnaire (GASP-Q) was used to assess the frequency and severity of the gastroesophageal reflux disease (GERD) symptoms: abdominal/belly pain, chest pain/heartburn, pain after eating, nausea, burping/belching, vomiting/regurgitation, choking when eating, and difficulty swallowing, in adolescents age 12 to 16 years. The primary objective was to compare the mean composite symptom score (CSS) at week 8 with baseline after treatment with 20 or 40 mg of pantoprazole. Statistically significant (p < 0.001) improvement in CSS occurred in both groups. Safety was comparable between the 2 groups. Pantoprazole was safe, well tolerated, and effective in reducing symptoms of GERD in adolescents.
Similar articles
-
Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease.J Pediatr Gastroenterol Nutr. 2006 Apr;42(4):384-91. doi: 10.1097/01.mpg.0000214160.37574.d3. J Pediatr Gastroenterol Nutr. 2006. PMID: 16641576 Clinical Trial.
-
Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.Clin Ther. 2010 Apr;32(4):678-90. doi: 10.1016/j.clinthera.2010.03.020. Clin Ther. 2010. PMID: 20435237 Review.
-
Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.Digestion. 2004;70(1):61-9. doi: 10.1159/000080130. Epub 2004 Aug 5. Digestion. 2004. PMID: 15297779 Clinical Trial.
-
Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease.J Pediatr Gastroenterol Nutr. 2007 Nov;45(5):520-9. doi: 10.1097/MPG.0b013e318148c17c. J Pediatr Gastroenterol Nutr. 2007. PMID: 18030228 Clinical Trial.
-
[Gastroesophageal reflux disease: pathogenesis, clinical manifestation, diagnostics, and treatment].Klin Med (Mosk). 2005;83(9):16-24. Klin Med (Mosk). 2005. PMID: 16279033 Review. Russian. No abstract available.
Cited by
-
Pantoprazole: a proton pump inhibitor.Clin Drug Investig. 2009;29 Suppl 2:3-12. doi: 10.2165/1153121-S0-000000000-00000. Clin Drug Investig. 2009. PMID: 19938880 Review.
-
Pharmacological treatment of gastro-oesophageal reflux in children.Cochrane Database Syst Rev. 2023 Aug 22;8(8):CD008550. doi: 10.1002/14651858.CD008550.pub3. Cochrane Database Syst Rev. 2023. PMID: 37635269 Free PMC article.
-
Dyspepsia in childhood and adolescence: insights and treatment considerations.Curr Gastroenterol Rep. 2007 Dec;9(6):447-55. doi: 10.1007/s11894-007-0058-4. Curr Gastroenterol Rep. 2007. PMID: 18377794 Review.
-
A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease.J Clin Pharmacol. 2011 Jun;51(6):876-87. doi: 10.1177/0091270010377501. Epub 2010 Sep 17. J Clin Pharmacol. 2011. PMID: 20852004 Free PMC article. Clinical Trial.
-
Comparative safety and efficacy of proton pump inhibitors in paediatric gastroesophageal reflux disease.Drug Saf. 2014 May;37(5):309-16. doi: 10.1007/s40264-014-0154-y. Drug Saf. 2014. PMID: 24706290 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
